Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I clinical study evaluating the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors through dose escalation and expansion

Next Previous
Trial Profile

A Phase I clinical study evaluating the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors through dose escalation and expansion

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GTA-182 (Primary)
  • Indications Bladder cancer; Carcinoma; Head and neck cancer; Mesothelioma; Nerve sheath neoplasms; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 15 Jan 2025 New trial record
  • 08 Jan 2025 First patient has been dosed.
  • 14 Oct 2024 According to Apeiron media release,the company receive the IND Clearance from China National Medical Products Administration (NMPA),for the treatment of MTAP-null solid tumors.Also the company plans to file an Investigational New Drug (IND) application with the US FDA for GTA182 in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top